Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Screening potential allergy vaccine components
NL-OMON54501Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- May 2022
- Modality
- Small Molecules, Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of vitamin d, tretinoin, house dust mite allergen der p1, Der p 2, Ara h 6 and 1 more in allergic rhinitis (AR), food allergy, house dust mite allergy and 4 more (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Allergen-specific IgE titer, PBMC isolation for in vitro immune assays and 1 more. Started May 2022; status: recruiting.
02
Drugs
vitamin dtretinoinhouse dust mite allergen der p1Der p 2Ara h 6
03
Conditions
allergic rhinitis (AR)food allergyhouse dust mite allergypeanut allergyCashew Allergy
Beyond the preview
Go deeper on NL-OMON54501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54501.